Departure and appointment · 16 October 2026
IRONWOOD PHARMACEUTICALS INC
IRWD · Listed
Key facts
- How the CEO left
- Retirement
- Planned or abrupt
- Planned
- Successor
- Internal (a current executive)
- Outgoing CEO stays as
- Board member
- Signs it was forced
- None stated
- Other news alongside
- None
- Effective
- 1 January 2027
- Reason given
- decision to retire
Read from the filing and press release by a language model (Google Gemini), told to use only that text. It can make mistakes; the quotes below are the source.
The announcement
Ironwood Pharmaceuticals, Inc. (the “Company”) today announced that, on October 12, 2026, the Board of Directors (the “Board”) appointed Tammi Gaskins, the Company’s Senior Vice President, Chief Commercial Officer, as Chief Executive Officer, effective January 1, 2027 (the “Transition Date”).
The Company also announced today that, on October 12, 2026, Thomas McCourt notified the Board of his decision to retire as Chief Executive Officer, effective December 31, 2026, following 17 years of service to the Company, including five years in that role.
In connection with her appointment as Chief Executive Officer and effective as of the Transition Date, Ms. Gaskins will receive an annual base salary of $775,000 and will have an individual bonus target of 75% of her annual base salary, subject to achievement of corporate goals.
The Company intends to enter into an amended and restated executive severance agreement (the “Agreement”) with Ms. Gaskins, effective as of the Transition Date, in connection with her appointment as the Company’s Chief Executive Officer.
Sentences matched by our CEO change rules, from the first filing. Read the 8-K on SEC EDGAR ↗
Share price reaction
The filing reached SEC EDGAR on 16 October 2026 at 11:30 New York time, during trading hours, so day 0 is that same day. Day 0 is marked by the vertical line.
| Window | IRWD | S&P 500 | Abnormal |
|---|---|---|---|
| Days 0 to +1 | −5.6% | −0.7% | −5.2% |
| Days 0 to +3 | −5.8% | +0.2% | −8.1% |
| 1 month (days 0 to +21)so far, 8 of 22 days | −6.9% | −0.3% | −10.5% |
| 3 months (days 0 to +63)so far, 8 of 64 days | −6.9% | −0.3% | −10.5% |
The abnormal return is the stock's return beyond what its usual relationship with the market (beta 1.87) predicts. A single stock's move can reflect other news on the same days, so it describes what happened rather than measuring the effect of the CEO change; averages across many events are on the Research design page as they are completed.
News coverage
No matching headlines found. Coverage is thinner for smaller companies.